Evidence map›Paper›PMID 41624949›Full record

ArticleRespiratory medicine case reports2026

Tepotinib-induced interstitial lung disease in a patient with adenosquamous lung carcinoma.

Takeshi Imakura, Soji Kakiuchi, Ikumi Nishimura, Naoya Murakami, Hiroki Yamamoto, Hitomi Kagawa, Mami Inayama, Takashi Haku

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Takeshi ImakuraDepartment of Respiratory Medicine, Tokushima Prefectural Central Hospital, Tokushima, Japan.
Soji KakiuchiDepartment of Respiratory Medicine, Tokushima Prefectural Central Hospital, Tokushima, Japan.
Ikumi NishimuraDepartment of Respiratory Medicine, Tokushima Prefectural Central Hospital, Tokushima, Japan.
Naoya MurakamiDepartment of Respiratory Medicine, Tokushima Prefectural Central Hospital, Tokushima, Japan.
Hiroki YamamotoDepartment of Respiratory Medicine, Tokushima Prefectural Central Hospital, Tokushima, Japan.
Hitomi KagawaDepartment of Respiratory Medicine, Tokushima Prefectural Central Hospital, Tokushima, Japan.
Mami InayamaDepartment of Respiratory Medicine, Tokushima Prefectural Central Hospital, Tokushima, Japan.
Takashi HakuDepartment of Respiratory Medicine, Tokushima Prefectural Central Hospital, Tokushima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a case of drug-induced lung injury in an 88-year-old man with non-small cell lung cancer harboring an MET exon 14 skipping mutation. The patient developed dyspnea and new ground-glass opacities shortly after the initiation of tepotinib, an oral MET-tyrosine kinase inhibitor (MET-TKI). Clinical findings and laboratory data supported the diagnosis of tepotinib-induced interstitial lung disease (ILD). High-dose corticosteroid therapy led to improvement, and the patient was discharged. This case underscores the potential of early onset ILD with tepotinib, especially in patients with possible pre-existing ILD. Close monitoring and early intervention are essential, and further studies are needed to clarify the risk factors for MET-TKI-induced ILD.

Indexed as

ILDLung cancerMET-TKITepotinib

Identifiers

PMID41624949
PMCPMC12854860

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.